{
  "id": 2467660,
  "title": "Aeon Biopharma director Timothy Lynch buys $243,455 in stock",
  "url": "https://urgent.news/2026/08/22/aeon-biopharma-director-timothy-lynch-buys-243-455-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-22T01:00:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/aeon-biopharma-director-timothy-lynch-buys-243455-in-stock-93CH-4872243"
  },
  "original_language": "en",
  "account": "Aeon Biopharma's Director Timothy Lynch increased his stake in the company by acquiring 1,150,000 shares of Class A Common Stock on August 19, 2026. The purchase, worth approximately $243,455, was made at an average price of $0.2117 per share, with individual prices ranging from $0.1975 to $0.2164. Following the transaction, Lynch's direct beneficial ownership of AEON Biopharma stands at 6,500,000 shares. This move comes as the stock trades near its 52-week low of $0.18, down 30% in the past week. Despite the recent decline, the stock is considered slightly undervalued by InvestingPro analysis, which offers 16 ProTips for further insights. Aeon Biopharma is currently advancing its biosimilar product, ABP-450, through the FDA's 351(k) pathway, with its analytical similarity strategy recently reviewed and approved. The company has also received a Buy rating from H.C. Wainwright, albeit with its price target lowered from $5.00 to $1.20.",
  "summary": null,
  "key_points": [
    "Timothy Lynch, Aeon Biopharma director, bought 1.15M shares on Aug 19, 2026",
    "Purchase valued at $243,455, average price $0.2117 per share",
    "Lynch now owns 6.5M shares, stock near 52-week low of $0.18"
  ],
  "editors_take": "Director Timothy Lynch's substantial stock purchase signals confidence in Aeon Biopharma's prospects despite the recent stock price decline, and may indicate an attractive entry point for other investors.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}